Tag: central nervous system
January 24, 2019
Seelos Therapeutics Announces Successful Completion of its Merger with Apricus Biosciences
Seelos Therapeutics (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical... November 29, 2018
VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with... October 3, 2018
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with... September 28, 2018
Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
Intra-Cellular Therapies (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced... July 30, 2018
Apricus Biosciences Announces Merger Agreement with Seelos Therapeutics
Apricus Biosciences (NASDAQ:APRI) has announced it has signed an agreement to merge with Seelos Therapeutics in an all-stock transaction. As...
May 13, 2018
5 Top Weekly NASDAQ Biotech Stocks: Helius Up 43.19 Percent
Helius Medical Technologies, vTv Therapeutics, Second Sight Medical Products, Depomed and Senomyx were last week's top gainers on the NASDAQ. May 9, 2018